Human DNA-binding protein SMUBP-2 (IGHMBP2) ELISA kit; CATF1; FLJ34220; FLJ41171; HCSA; HMN6; SMARD1; SMUBP2; cardiac transcription factor 1; immunoglobulin mu binding protein 2

For Research Use Only. Not for use in diagnostic procedures.

Store all reagents at 2-8 degree C

Select online data sheet information is drawn from bioinformatics databases, occasionally resulting in ambiguous or non-relevant product information. It is the responsibility of the customer to review, verify, and evaluate the information to make sure it matches their requirements before purchasing the kit. Our ELISA Kit assays are dynamic research tools and sometimes they may be updated and improved. If the format of this assay is important to you then please request the current manual or contact our technical support team with a presales inquiry before placing an order. We will confirm the current details of the assay. We cannot guarantee the sample manual posted online is the most current manual.

Small volumes of IGHMBP2 elisa kit vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

MBS9320245 is a ready-to-use microwell, strip plate ELISA (enzyme-linked immunosorbent assay) Kit for analyzing the presence of the immunoglobulin mu binding protein 2 (IGHMBP2) ELISA Kit target analytes in biological samples. The concentration gradients of the kit standards or positive controls render a theoretical kit detection range in biological research samples containing IGHMBP2. The ELISA analytical biochemical technique of the MBS9320245 kit is based on IGHMBP2 antibody-IGHMBP2 antigen interactions (immunosorbency) and an HRP colorimetric detection system to detect IGHMBP2 antigen targets in samples. The ELISA Kit is designed to detect native, not recombinant, IGHMBP2. Appropriate sample types may include undiluted body fluids and/or tissue homogenates, secretions. Quality control assays assessing reproducibility identified the intra-assay CV (%) and inter-assay CV(%).

109,149 Da

immunoglobulin mu binding protein 2

DNA-binding protein SMUBP-2; GF-1; glial factor 1; ATP-dependent helicase IGHMBP2; cardiac transcription factor 1; zinc finger, AN1-type domain 7; immunoglobulin mu-binding protein 2

DNA-binding protein SMUBP-2

SMBP2; SMUBP2; GF-1??[Similar Products]

SMBP2_HUMAN

This gene encodes a helicase superfamily member that binds a specific DNA sequence from the immunoglobulin mu chain switch region. Mutations in this gene lead to spinal muscle atrophy with respiratory distress type 1. [provided by RefSeq, Jul 2008]

IGHMBP2: 5' to 3' helicase that unwinds RNA and DNA duplices in an ATP-dependent reaction. Acts as a transcription regulator. Required for the transcriptional activation of the flounder liver- type antifreeze protein gene. Exhibits strong binding specificity to the enhancer element B of the flounder antifreeze protein gene intron. Binds to the insulin II gene RIPE3B enhancer region. May be involved in translation. DNA-binding protein specific to 5'-phosphorylated single-stranded guanine-rich sequence related to the immunoglobulin mu chain switch region. Preferentially binds to the 5'-GGGCT-3' motif. Interacts with tRNA-Tyr. Stimulates the transcription of the human neurotropic virus JCV. Defects in IGHMBP2 are the cause of distal hereditary motor neuronopathy type 6 (HMN6); also known as spinal muscular atrophy distal autosomal recessive 1 (DSMA1) or spinal muscular atrophy with respiratory distress 1 (SMARD1). Distal hereditary motor neuronopathies constitute a heterogeneous group of neuromuscular disorders caused by selective degeneration of motor neurons in the anterior horn of the spinal cord, without sensory deficit in the posterior horn. The overall clinical picture consists of a classical distal muscular atrophy syndrome in the legs without clinical sensory loss. The disease starts with weakness and wasting of distal muscles of the anterior tibial and peroneal compartments of the legs. Later on, weakness and atrophy may expand to the proximal muscles of the lower limbs and/or to the distal upper limbs. The most prominent symptoms of HMN6 are severe respiratory distress resulting from diaphragmatic paralysis with eventration shown on chest x-ray and predominant involvement of the upper limbs and distal muscles. Belongs to the DNA2/NAM7 helicase family.

Protein type: DNA-binding; EC 3.6.4.13; EC 3.6.4.12; Helicase

Chromosomal Location of Human Ortholog: 11q13.3

Cellular Component: growth cone; membrane; axon; cytoplasm; SMN complex; nucleus; ribonucleoprotein complex

Molecular Function: DNA-dependent ATPase activity; RNA-dependent ATPase activity; zinc ion binding; RNA binding; ATP-dependent 5'-3' DNA helicase activity; ribosome binding; transcription factor binding; tRNA binding; protein binding; DNA helicase activity; DNA binding; ATP-dependent 5'-3' RNA helicase activity; single-stranded DNA binding; ATP binding

Biological Process: translation; regulation of transcription, DNA-dependent; transcription, DNA-dependent; DNA replication; DNA repair; DNA duplex unwinding; protein homooligomerization; DNA recombination

Disease: Charcot-marie-tooth Disease, Axonal, Type 2s; Spinal Muscular Atrophy, Distal, Autosomal Recessive, 1

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.